Published in J Nucl Med on January 01, 1999
Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging (2010) 1.61
Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur J Nucl Med Mol Imaging (2002) 0.88
Radioiodine Scan Index: A Simplified, Quantitative Treatment Response Parameter for Metastatic Thyroid Carcinoma. Nucl Med Mol Imaging (2015) 0.84
Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging (2008) 0.84
Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck. Eur J Nucl Med Mol Imaging (2011) 0.82
Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2011) 0.82
Novel Approaches to Thyroid Cancer Treatment and Response Assessment. Semin Nucl Med (2016) 0.77
Development of an athyroid mouse model using (131)I ablation after preparation with a low-iodine diet. Sci Rep (2017) 0.75
Challenging cases in thyroid cancer: a multidisciplinary approach. Eur J Nucl Med Mol Imaging (2003) 0.75
Radiometric detection of the metabolic activity of Mycobacterium tuberculosis. J Nucl Med (1975) 5.30
Automated detection of Haemophilus influenzae. Appl Microbiol (1973) 3.16
Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer (1997) 2.81
Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res (1998) 2.55
A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res (1998) 2.43
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol (1999) 2.38
Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst (1991) 2.19
Imaging transgene expression with radionuclide imaging technologies. Neoplasia (2000) 2.03
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol (1989) 2.00
Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol (2002) 1.96
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med (1999) 1.95
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab (1999) 1.90
Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. Arch Pathol Lab Med (2000) 1.74
Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys (2004) 1.74
Quantitative imaging of iodine-124 with PET. J Nucl Med (1996) 1.69
Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med (1998) 1.67
Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid (2000) 1.59
Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab (2000) 1.59
Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol (1998) 1.56
Phase and amplitude binning for 4D-CT imaging. Phys Med Biol (2007) 1.52
Radiopharmacology of a simplifield technetium-99m-colloid preparation for photoscanning. J Nucl Med (1966) 1.49
FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med (2001) 1.49
Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer. Med Phys (2002) 1.48
In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med (1989) 1.43
Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest (1983) 1.42
Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol (1988) 1.41
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol (1994) 1.41
In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med (1990) 1.41
Triumph over mischance: a role for nuclear medicine in gene therapy. J Nucl Med (1997) 1.41
Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg (1999) 1.41
Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology (2001) 1.40
Quantitative bone metastases analysis based on image segmentation. J Nucl Med (1997) 1.36
Quantitation of respiratory motion during 4D-PET/CT acquisition. Med Phys (2004) 1.35
Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol (1993) 1.35
Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep (1984) 1.35
3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol (1998) 1.35
Dimensions of the normal adult spleen scan and prediction of spleen weight. J Nucl Med (1971) 1.33
Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med (1986) 1.27
Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg (1985) 1.27
Midazolam changes cerebral blood flow in discrete brain regions: an H2(15)O positron emission tomography study. Anesthesiology (1997) 1.25
A general approach to the non-invasive imaging of transgenes using cis-linked herpes simplex virus thymidine kinase. Neoplasia (1999) 1.25
Imaging of melanoma with L-131-labeled monoclonal antibodies. J Nucl Med (1983) 1.24
Effects of obstetrician gender on communication and patient satisfaction. Obstet Gynecol (1999) 1.23
Use-dependent structural events in recovery of function. Adv Neurol (1997) 1.23
Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab (2013) 1.21
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol (1996) 1.21
The radionuclide ejection fraction: a comparison of three radionuclide techniques with contrast angiography. J Nucl Med (1977) 1.18
Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid (2001) 1.17
Contribution of the liver to overall elimination of propranolol. J Pharmacokinet Biopharm (1976) 1.16
The pharmacology of monoclonal antibodies. Ann N Y Acad Sci (1987) 1.15
Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy. J Nucl Med (1985) 1.14
Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J Nucl Med (1996) 1.13
Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res (2001) 1.12
Hypoxia-Induced increase in FDG uptake in MCF7 cells. J Nucl Med (2001) 1.12
Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia (2001) 1.11
Evaluation of an automated deformable image matching method for quantifying lung motion in respiration-correlated CT images. Med Phys (2006) 1.10
Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy. Med Phys (1997) 1.10
Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol (2001) 1.10
Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation (1987) 1.09
Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol (2006) 1.09
An unusual cause of partial ETT obstruction. Anesthesiology (1998) 1.09
Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med (1988) 1.08
Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer. Nat Med (2001) 1.08
Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis. Radiat Res (1992) 1.07
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res (1998) 1.07
Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med (2000) 1.07
Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol (1994) 1.06
Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res (1994) 1.05
Visualization of the placenta by radioisotope photoscanning using technetium-99m-labeled albumin. Am J Obstet Gynecol (1965) 1.04
Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol (1996) 1.03
Radioimmunodetection in cancer identification. J Nucl Med (1992) 1.02
Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med (2001) 1.02
Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys (1991) 0.99
Acquired immunodeficiency syndrome: Ga-67 citrate imaging. Radiology (1987) 0.99
N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol (2001) 0.98
Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications. Int J Rad Appl Instrum B (1989) 0.97
An automated system for measurement of leukocyte metabolism. J Nucl Med (1974) 0.96
Jod-Basedow syndrome following oral iodine and radioiodinated-antibody administration. J Nucl Med (1997) 0.96
Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant (2003) 0.95
Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl Med (1997) 0.95
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid (2001) 0.95
Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma. Clin Cancer Res (1998) 0.94
Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med (1993) 0.94
Lymphoscintigraphy and sentinel node localization in breast cancer patients: a comparison between 1-day and 2-day protocols. J Nucl Med (2001) 0.94
Radiometric measurement of differential metabolism of fatty acid by mycobacteria. Int J Lepr Other Mycobact Dis (1982) 0.93
Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3. Int J Cancer (1987) 0.93
Prenatal genetic testing: content of discussions between obstetric providers and pregnant women. Obstet Gynecol (1998) 0.93
Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. J Nucl Med (1999) 0.93
Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft. J Nucl Med (2001) 0.93